Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report
Lung cancer stands as a leading cause of mortality in China, with EGFR mutations frequently identified as pivotal driver genes. Osimertinib, a tyrosine kinase inhibitor targeting EGFR mutations, is typically employed as a first-line treatment for EGFR-sensitive mutations; nevertheless, resistance ca...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023097232 |
| _version_ | 1797429648681861120 |
|---|---|
| author | Siqi Xiang Liang Zeng Mingjun Xiang Yongchang Zhang |
| author_facet | Siqi Xiang Liang Zeng Mingjun Xiang Yongchang Zhang |
| author_sort | Siqi Xiang |
| collection | DOAJ |
| description | Lung cancer stands as a leading cause of mortality in China, with EGFR mutations frequently identified as pivotal driver genes. Osimertinib, a tyrosine kinase inhibitor targeting EGFR mutations, is typically employed as a first-line treatment for EGFR-sensitive mutations; nevertheless, resistance can emerge. In this case report, we present the case of a 53-year-old non-smoking male diagnosed with stage IV lung adenocarcinoma bearing an EGFR exon 19 deletion. This patient eventually developed resistance to both Erlotinib and Osimertinib after 28 months of treatment. Subsequent genetic testing uncovered the emergence of new MET exon 14 skipping and MET fusion, coexisting with the initial EGFR exon 19 deletion. In light of this complex molecular profile, the patient was administered a combination therapy consisting of Osimertinib and Capmatinib. This novel approach yielded a partial response, and notably, the patient experienced a progression-free survival exceeding 7 months. Vigilant monitoring of the patient's progress revealed the disappearance of the MET exon 14 skipping and a notable improvement in the patient's symptoms. This case report underscores the potential efficacy of Osimertinib and Capmatinib combination therapy as a viable treatment strategy for patients harboring EGFR-mutated lung cancer who develop resistance to first-line EGFR inhibitors due to MET activation. |
| first_indexed | 2024-03-09T09:16:09Z |
| format | Article |
| id | doaj.art-d031b2eaa3d244ce94ceeb5d6b22e885 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-09T09:16:09Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-d031b2eaa3d244ce94ceeb5d6b22e8852023-12-02T07:06:04ZengElsevierHeliyon2405-84402023-11-01911e22515Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case reportSiqi Xiang0Liang Zeng1Mingjun Xiang2Yongchang Zhang3Department of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, 416000, China; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, ChinaDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, ChinaDepartment of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, 416000, ChinaDepartment of Biochemistry and Immunology, Medical Research Center, Institute of Medicine, Jishou University, Jishou, 416000, China; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China; Corresponding author. Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University; Changsha, 410013, China.Lung cancer stands as a leading cause of mortality in China, with EGFR mutations frequently identified as pivotal driver genes. Osimertinib, a tyrosine kinase inhibitor targeting EGFR mutations, is typically employed as a first-line treatment for EGFR-sensitive mutations; nevertheless, resistance can emerge. In this case report, we present the case of a 53-year-old non-smoking male diagnosed with stage IV lung adenocarcinoma bearing an EGFR exon 19 deletion. This patient eventually developed resistance to both Erlotinib and Osimertinib after 28 months of treatment. Subsequent genetic testing uncovered the emergence of new MET exon 14 skipping and MET fusion, coexisting with the initial EGFR exon 19 deletion. In light of this complex molecular profile, the patient was administered a combination therapy consisting of Osimertinib and Capmatinib. This novel approach yielded a partial response, and notably, the patient experienced a progression-free survival exceeding 7 months. Vigilant monitoring of the patient's progress revealed the disappearance of the MET exon 14 skipping and a notable improvement in the patient's symptoms. This case report underscores the potential efficacy of Osimertinib and Capmatinib combination therapy as a viable treatment strategy for patients harboring EGFR-mutated lung cancer who develop resistance to first-line EGFR inhibitors due to MET activation.http://www.sciencedirect.com/science/article/pii/S2405844023097232MET exon 14 skippingMET fusionResistance mechanismOsimertinibCapmatinibEGFR |
| spellingShingle | Siqi Xiang Liang Zeng Mingjun Xiang Yongchang Zhang Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report Heliyon MET exon 14 skipping MET fusion Resistance mechanism Osimertinib Capmatinib EGFR |
| title | Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report |
| title_full | Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report |
| title_fullStr | Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report |
| title_full_unstemmed | Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report |
| title_short | Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report |
| title_sort | presence of met exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an egfr exon 19 deletion that responds to combination of capmatinib and osimertinb a case report |
| topic | MET exon 14 skipping MET fusion Resistance mechanism Osimertinib Capmatinib EGFR |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023097232 |
| work_keys_str_mv | AT siqixiang presenceofmetexon14skippingandfusionasmechanismofosimertinbresistanceinalungadenocarcinomawithanegfrexon19deletionthatrespondstocombinationofcapmatinibandosimertinbacasereport AT liangzeng presenceofmetexon14skippingandfusionasmechanismofosimertinbresistanceinalungadenocarcinomawithanegfrexon19deletionthatrespondstocombinationofcapmatinibandosimertinbacasereport AT mingjunxiang presenceofmetexon14skippingandfusionasmechanismofosimertinbresistanceinalungadenocarcinomawithanegfrexon19deletionthatrespondstocombinationofcapmatinibandosimertinbacasereport AT yongchangzhang presenceofmetexon14skippingandfusionasmechanismofosimertinbresistanceinalungadenocarcinomawithanegfrexon19deletionthatrespondstocombinationofcapmatinibandosimertinbacasereport |